dexanabinol

(6aS-trans)-3-(1,1- dimethyl heptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo(b,d)pyran-9-methanol 1,1- dimethyl heptyl-11-hydroxytetrahydrocannabinol 1,1- dimethylheptyl-11-hydroxytetrahydrocannabinol HU 211 11- hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl (6aS,10aS)-9-( hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol sinnabidiol PubMed: Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles. PubMed: A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. PubMed: Use of magnesium in traumatic brain injury. PubMed: Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. PubMed: Importance of screening logs in clinical trials for severe traumatic brain injury. PubMed: The protective effect of dexanabinol (HU-211) on nitric oxide and cysteine protease-mediated neuronal death in focal cerebral ischemia. PubMed: Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. PubMed: Dexanabinol prevents development of vasospasm in the rat femoral artery model. PubMed: Observer variation in the assessment of outcome in traumatic brain injury: experience from a multicenter, international randomized clinical trial. PubMed: Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. PubMed: [The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans]. PubMed: Gateways to clinical trials. PubMed: Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. PubMed: Gateways to clinical trials. PubMed: Gateways to clinical trials. PubMed: Recent advances in the development of multifactorial therapies for the treatment of traumatic brain injury. PubMed: Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies. PubMed: The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). PubMed: Synergism between tumor necrosis factor-alpha and H2O2 enhances cell damage in rat PC12 cells. PubMed: [New therapies for intracranial hypertension]. PubMed: Gateways to clinical trials. PubMed: Dexanabinol: a novel cannabinoid with neuroprotective properties. PubMed: Combination of dexanabinol and tempol in focal cerebral ischemia: is there a ceiling effect? PubMed: Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. PubMed: Therapeutic potential of cannabinoids in CNS disease. PubMed: Promising strategies to minimize secondary brain injury after head trauma. PubMed: Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury. PubMed: Dexanabinol as a treatment for traumatic brain injury: will another therapeutic promise be broken? PubMed: Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. PubMed: The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. PubMed: Attempts of ranking in a series of synthetic nonpsychotropic cannabinoids. PubMed: Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. PubMed: Dexanabinol Pharmos. PubMed: Nonpsychotropic synthetic cannabinoids. PubMed: Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. PubMed: Water-soluble combinations of dexanabinol: prodrugs and analogs. PubMed: Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures. PubMed: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. PubMed: In vitro and in vivo study of water-soluble prodrugs of dexanabinol. PubMed: Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. PubMed: Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. PubMed: Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. PubMed: Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. PubMed: Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. PubMed: Derivatives of dexanabinol. II. Salts of amino acid esters containing tertiary and quaternary heterocyclic nitrogen with increased water-solubility. PubMed: Derivatives of Dexanabinol. I. Water-soluble salts of glycinate esters. PubMed: Development of HU-211 as a neuroprotectant for ischemic brain damage.